Patient-Reported Food Noise, Cravings and Appetite in Adults with Obesity Treated with Weekly Injectable GLP-1 Based Therapies: A Prospective Real-World Study
Aims: Although pivotal trials have established efficacy in weight reduction during the use of GLP-1 based therapies, daily fluctuations in food-related experiences between scheduled assessments remain to be better characterized. We therefore aimed to assess day-to-day patterns in food noise, cravings, hunger, satiety, and fullness among adults receiving weekly semaglutide or tirzepatide for weight management. Materials and Methods: This prospective, direct-to-participant, US observational study enrolled adults receiving weekly subcutaneous semaglutide or tirzepatide for weight management with self-reported BMI ≥ 30 kg/m 2 before treatment initiation. Participants completed daily 24-hour-recall electronic diaries assessing food-related experiences for 6 weeks. Each injection defined Day 1 of a new dosing cycle. Results: Of 275 enrolled participants, 237 (86%) were included in the analysis. Daily food noise prevalence ranged from 4.3% to 23.8% over 6 weeks, generally highest on dosing day, declining thereafter, and returning toward dosing-day levels by Day 7. Overall, 182 participants (76.8%) reported food cravings at least once over 6 weeks, with moderate craving intensity as most frequently reported (98/237 [41.4%]). Across the study period, mean visual analog scale (0-100) on cycle Days 1, 2, and 7 were 39.9, 31.1, and 41.6 for hunger; 66.3, 69.8, and 64.2 for satiety; and 62.0, 65.1, and 60.6 for fullness. Conclusions: Food noise, cravings, and hunger declined soon after GLP-1 based therapy administration and increased towards the end of the weekly interval, whereas fullness and satiety fluctuated less. Daily assessments may capture experiences missed by conventional trial visit schedules and may be particularly relevant as therapies with longer half-lives become available.
Authors
- Bethany A. Kalich (ORCID: https://orcid.org/0000-0002-1220-3484)
- Carel Wynand le Roux (ORCID: https://orcid.org/0000-0001-5521-5445)
- Min‐Jung Wang (ORCID: https://orcid.org/0000-0003-4432-3330)
- Deborah Bade Horn (ORCID: https://orcid.org/0000-0003-3493-9609)
- Zhengrong Li (ORCID: https://orcid.org/0000-0001-7304-6729)
- Kate K. Orroth (ORCID: https://orcid.org/0000-0002-4950-3149)
- Chalak Muhammad (ORCID: https://orcid.org/0009-0004-0123-8667)
- Abd A. Tahrani (ORCID: https://orcid.org/0000-0001-9037-1937)
- Yu Mi Kang (ORCID: https://orcid.org/0000-0002-6272-0666)
- Suna Avcil
- Lam Nguyen
- C. Michael Gibson
- Stephen Fabiano
- Leandro Boer (ORCID: https://orcid.org/0000-0003-3185-9144)
Institutions
- University College Dublin (IE)
- Beth Israel Deaconess Medical Center (US)
- Amgen (United States) (US)
- Harvard University (US)
- Qiagen (Denmark) (DK)
- The University of Texas Health Science Center (US)
- Mass General Brigham (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-13
- DOI
- https://doi.org/10.64898/2026.11.13.26367932
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- preprint